1042 Live Notices for Western Europe Health Insurance Tenders
Showing 1 to 20
Printing And Shipping Services For Customer Magazines
17 Dec 2024
29 Jan 2025Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Ranolazine, (Obg) Atc C01Eb18 For The Period 01.02.2025 - 31.03.2025
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) For The Active Ingredient Perindopril And Indapamide (Excluding Perindopril As Arginine Salt), Atc C09Ba54 For The Period 01.02.25 - 31.01.27
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) For The Active Ingredient Peg-Epoetin Beta, (Obo) Atc B03Xa03 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V For The Active Ingredient Aripiprazole (Excl. Dafo For The Production Of A Dis), (Obo) Atc N05Ax12 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Flupentixol, (Obg) Atc N05Af01 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) For The Active Ingredient Perindopril And Indapamide (Excluding Perindopril As Arginine Salt), Atc C09Ba54 For The Period 01.02.25 - 31.01.27
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Ranolazine, (Obg) Atc C01Eb18 For The Period 01.02.2025 - 31.03.2025
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb) V For The Active Ingredient Lipegfilgrastim, (Obo) Atc L03Aa14 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) For The Active Ingredient Peg-Epoetin Beta, (Obo) Atc B03Xa03 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Code Book V For The Active Ingredient Aripiprazole (Excl. Dafo For The Production Of A Dis), (Obo) Atc N05Ax12 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Flupentixol, (Obg) Atc N05Af01 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Of The Social Security Code (Sgb V) For The Active Ingredient Perindopril And Indapamide (Excluding Perindopril As Arginine Salt), Atc C09Ba54 For The Period 01.02.25 - 31.01.27
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Ranolazine, (Obg) Atc C01Eb18 For The Period 01.02.2025 - 31.03.2025
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Baricitinib, (Obo) Atc L04Aa37 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Mepolizumab, (Obo) Atc R03Dx09 For The Period 01.02.2025 - 31.01.2027
Conclusion Of A Non-Exclusive Discount Agreement Pursuant To Section 130A Paragraph 8 Sgb V For The Active Ingredient Lipegfilgrastim, (Obo) Atc L03Aa14 For The Period 01.02.2025 - 31.01.2027
Tenders by Country